Regeneron And Sanofi Announce EU Approval For Anti-Cholesterol Drug Praluent Praluent is now going to be made available in Europe as the European Commission signs off on the anti-cholesterol drug from Regeneron and Sanofi. by Dianne Depra
Healthy Living/Wellness New Cholesterol Drugs Are Too Expensive: Independent Study Concludes by Ted Ranosa
Healthy Living/Wellness FDA Gives Nod To Praluent: New Class Of Cholesterol-Lowering Drug Is Pricey by James Maynard
Healthy Living/Wellness FDA Approves Cholesterol-Lowering Drug Praluent By Regeneron And Sanofi: $15,000 A Year, Anyone? by Jill Arce